+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-amyloid Drugs Market - Global Forecast 2025-2030- Product Image
Anti-amyloid Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Anti-amyloid Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6124246
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Anti-amyloid therapeutics are rapidly redefining the neurodegenerative disease treatment landscape, as advances in precision drug development and regulatory pathways open new avenues for targeted, disease-modifying care. Market participants are repositioning in response to shifting trial designs, supply chain disruptions, and a heightened focus on access and patient outcomes.

Market Snapshot of the Anti-Amyloid Therapeutics Sector

The anti-amyloid therapeutics market is experiencing notable growth, propelled by increased focus on disease-modifying therapies for conditions such as Alzheimer’s and Parkinson’s. Innovations spanning monoclonal antibodies, small molecule inhibitors, vaccines, and peptide-based treatments reflect a broadening market characterized by significant R&D investments and evolving regulatory incentives. The rising prevalence of neurodegenerative diseases and the global pursuit of improved patient outcomes contribute to an expanding commercial landscape, creating new opportunities across established and emerging markets. Stakeholders include pharmaceutical leaders, biotech innovators, healthcare providers, and advocacy groups working collaboratively to translate scientific progress into accessible therapies.

Scope & Segmentation: Anti-Amyloid Therapeutics Market

This report comprehensively analyzes the latest trends and strategic shifts within the anti-amyloid therapeutics market. The primary keyword, anti-amyloid therapeutics, is integral to all main segmentations and underpins each area of innovation and development. Detailed segmentation covers:

  • Drug Types: Monoclonal antibodies (chimeric, fully human, humanized, murine), peptide-based therapies, small molecule inhibitors (aggregation inhibitors, secretase inhibitors), vaccines (DNA and peptide).
  • Indications: Alzheimer’s disease, Huntington’s disease, multiple sclerosis, Parkinson’s disease.
  • Routes of Administration: Intrathecal, intravenous (inpatient and outpatient infusion), oral (capsule, liquid, tablet), subcutaneous.
  • End Users: Home care settings, hospitals, specialty clinics.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Patient Stages: Early, mid, late disease progression.
  • Geographic Regions: Americas (United States with key states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (major countries including UK, Germany, France, and several emerging markets), Asia-Pacific (China, India, Japan, Australia, and others).
  • Company Coverage: Biogen Inc.; Eisai Co., Ltd.; Eli Lilly and Company; Roche Holding AG; Johnson & Johnson; AC Immune SA; Alzheon, Inc.; BioArctic AB; Novartis AG; and Denali Therapeutics, Inc.

Key Takeaways for Senior Decision-Makers

  • Anti-amyloid therapies now target disease biology directly, moving beyond symptomatic management and fostering a pipeline of innovative modalities.
  • Recent advances in biomarker technologies and adaptive clinical trial methodologies have accelerated regulatory approval timelines while enhancing trial precision.
  • Strategic collaboration among academic researchers, biotechs, pharmaceuticals, and manufacturing organizations is intensifying, supporting faster validation and commercialization of new candidates.
  • Regional market dynamics create unique pathways to access, as stakeholder engagement, reimbursement models, and patient needs vary across established and emerging territories.
  • Robust segmentation by drug category, indication, route, and patient stage empowers organizations to identify high-value opportunities and align investment with shifting care demands.
  • Supply chain resilience, including alternate sourcing and manufacturing models, is rapidly becoming critical as tariff and trade policy uncertainty rises.

Tariff Impact: U.S. Policy Changes and Operational Strategies

New United States tariff measures announced for 2025 are set to affect the pricing and supply chain structure of anti-amyloid drug manufacturing. Increased duties on imported raw materials, reagents, and biologic components are likely to drive reassessment of supplier portfolios, with an emphasis on long-term contracts and domestic manufacturing expansion. Companies are diversifying sourcing and employing supply chain risk strategies, including collaborations with contract manufacturing organizations outside tariff zones, to mitigate market disruptions and protect R&D productivity. Finance and procurement teams are updating pricing and reimbursement models to justify incremental adjustments and maintain market competitiveness.

Methodology & Data Sources

This report employs a multi-layered methodology, combining primary insights from interviews with industry stakeholders and secondary research from journals, trial registries, regulatory filings, and proprietary databases. Triangulation, scenario modeling, and expert validation ensure findings in the anti-amyloid therapeutics market are robust and actionable.

Why This Report Matters

  • Gain a strategic understanding of shifting R&D, investment, and regulatory dynamics critical for commercially successful anti-amyloid launches.
  • Identify actionable opportunities for market expansion, patient engagement, and operational resilience in a complex and evolving global market.
  • Leverage granular segmentation and regional insights to optimize partnerships, manufacturing strategies, and regulatory interactions.

Conclusion

The anti-amyloid therapeutics market is entering a transformative era characterized by scientific innovation, strategic collaboration, and evolving regulatory and operational practices. Forward-looking stakeholders are well positioned to drive growth and improve neurodegenerative disease outcomes globally.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Unexpected real-world efficacy outcomes from recently approved anti-amyloid therapies like lecanemab and donanemab impacting adoption dynamics
5.2. Advanced cerebrospinal fluid and PET imaging biomarker-driven patient stratification improving clinical trial success in anti-amyloid drug development
5.3. Competitive landscape shifting with emerging oral BACE inhibitors challenging monoclonal antibody dominance in Alzheimer's therapy
5.4. Evolving payer reimbursement frameworks addressing high-price anti-amyloid treatments based on long-term cognitive outcome data
5.5. Integration of artificial intelligence and digital biomarkers for early Alzheimer's detection and optimized anti-amyloid treatment timing
5.6. Intensified safety monitoring protocols following ARIA cases in diverse patient populations on anti-amyloid immunotherapy regimens
5.7. Strategic partnerships between pharma and diagnostics firms accelerating companion test development for precision anti-amyloid therapy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-amyloid Drugs Market, by Drug Type
8.1. Introduction
8.2. Monoclonal Antibodies
8.2.1. Chimeric
8.2.2. Fully Human
8.2.3. Humanized
8.2.4. Murine
8.3. Peptide-Based Therapies
8.4. Small Molecule Inhibitors
8.4.1. Aggregation Inhibitors
8.4.2. Secretase Inhibitors
8.5. Vaccines
8.5.1. DNA Vaccines
8.5.2. Peptide Vaccines
9. Anti-amyloid Drugs Market, by Indication
9.1. Introduction
9.2. Alzheimer's Disease
9.3. Huntington's Disease
9.4. Multiple Sclerosis
9.5. Parkinson's Disease
10. Anti-amyloid Drugs Market, by Route of Administration
10.1. Introduction
10.2. Intrathecal
10.3. Intravenous
10.3.1. Inpatient Infusion
10.3.2. Outpatient Infusion
10.4. Oral
10.4.1. Capsule
10.4.2. Liquid
10.4.3. Tablet
10.5. Subcutaneous
11. Anti-amyloid Drugs Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Anti-amyloid Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Anti-amyloid Drugs Market, by Patient Stage
13.1. Introduction
13.2. Early Stage
13.3. Late Stage
13.4. Mid Stage
14. Americas Anti-amyloid Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Anti-amyloid Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Anti-amyloid Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Biogen Inc.
17.3.2. Eisai Co., Ltd.
17.3.3. Eli Lilly and Company
17.3.4. Roche Holding AG
17.3.5. Johnson & Johnson
17.3.6. AC Immune SA
17.3.7. Alzheon, Inc.
17.3.8. BioArctic AB
17.3.9. Novartis AG
17.3.10. Denali Therapeutics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTI-AMYLOID DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTI-AMYLOID DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTI-AMYLOID DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTI-AMYLOID DRUGS MARKET: RESEARCHAI
FIGURE 28. ANTI-AMYLOID DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTI-AMYLOID DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. ANTI-AMYLOID DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-AMYLOID DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE-BASED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE-BASED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY AGGREGATION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY AGGREGATION INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SECRETASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SECRETASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INPATIENT INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INPATIENT INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY OUTPATIENT INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY OUTPATIENT INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY LATE STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MID STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ANTI-AMYLOID DRUGS MARKET SIZE, BY MID STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ANTI-AMYLOID DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 161. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 162. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 163. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 168. CANADA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 281. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 282. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 283. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 284. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 285. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 287. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 288. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 289. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 294. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 295. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 296. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 297. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 302. GERMANY ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 303. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 304. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 305. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 306. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 307. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 308. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 309. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 310. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 311. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 316. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 317. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 318. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 319. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
TABLE 324. FRANCE ANTI-AMYLOID DRUGS MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
TABLE 325. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 326. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 327. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 328. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 329. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 330. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 331. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 332. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 333. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 334. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 335. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 336. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 337. RUSSIA ANTI-AMYLOID DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-amyloid Drugs market report include:
  • Biogen Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Roche Holding AG
  • Johnson & Johnson
  • AC Immune SA
  • Alzheon, Inc.
  • BioArctic AB
  • Novartis AG
  • Denali Therapeutics, Inc.

Related Reports

Anti-amyloid Therapy Market - Global Forecast 2025-2030 - Product Image

Anti-amyloid Therapy Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Anti-amyloid-ß Monoclonal Antibodies Market - Global Forecast 2025-2030 - Product Image

Anti-amyloid-ß Monoclonal Antibodies Market - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Cerebral Amyloid Angiopathy Treatment Global Market Report 2025 - Product Image

Cerebral Amyloid Angiopathy Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025 - Product Image

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Amyloid Beta-protein Inhibitors - Pipeline Insight, 2025 - Product Image

Amyloid Beta-protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.